Used in cancer immunotherapy research, particularly in targeting PRAME (Preferentially Expressed Antigen in Melanoma), a protein overexpressed in various tumors including melanoma, lung, breast, and hematologic cancers. This reference antibody serves as a critical tool for validating PRAME expression in tumor tissues, enabling the development of targeted therapies such as CAR-T cells, bispecific antibodies, and other immuno-oncology agents. It supports assay development for patient stratification by identifying those most likely to respond to PRAME-directed treatments. Due to its high specificity and well-characterized binding properties, it is used as a benchmark in diagnostic test development and therapeutic antibody optimization. Its role in preclinical studies helps establish safety and efficacy profiles for emerging cancer therapies.